Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 5/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.72 |
| ▸ | TTR | P02766 | 4/20 | 0.72 |
| ▸ | NQO2 | P16083 | 4/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 3/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | BCR | P11274 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | AHR | P35869 | 2/20 | 0.70 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.70 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.70 |
| ▸ | TUBB | P07437 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resveratrol 4'-Methyl Ether SCHEMBL563262 | 1.00 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| Resveratrol 4'-Methyl Ether SCHEMBL563261 | 1.00 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL15026080 | 0.92 | PTGS2 (0.85) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL29652111 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL2516446 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL2516449 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL29662231 | 0.92 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL12307322 | 0.89 | PTGS2 (0.79) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL8396878 | 0.87 | PTGS2 (0.77) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 | |
| SCHEMBL12567384 | 0.87 | PTGS2 (0.77) | PTGS2CYP1A1CYP1B1KDM4EPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | claimed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | claimed |
| US-20210106728-A1 | METHODS AND DEVICES FOR REDUCING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-04-15 | — | — | US | disclosed |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-10-16 | — | — | US | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150190253-A1 | COATED DEVICES AND METHODS OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2015-07-09 | — | — | US | disclosed |
| US-20150190253-A1 | COATED DEVICES AND METHODS OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2015-07-09 | — | — | US | disclosed |
| US-8992471-B2 | Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity | NANOCOPOEIA, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8992471-B2 | Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity | NANOCOPOEIA, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2719395-A1 | Adsorption of immunopotentiators to insoluble metal salts | Novartis AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| US-20100331965-A1 | COATED DEVICES AND METHOD OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY | NANOCOPOEIA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331965-A1 | COATED DEVICES AND METHOD OF MAKING COATED DEVICES THAT REDUCE SMOOTH MUSCLE CELL PROLIFERATION AND PLATELET ACTIVITY | NANOCOPOEIA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106728-A1 | METHODS AND DEVICES FOR REDUCING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | VCAM1, MYLK, TNNC1 | PTGS2 1828/4885CYP1A1 4718/4885CYP1B1 4683/4885 |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | PTGS2 28/4885CYP1A1 1123/4885CYP1B1 1133/4885 |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | PTGS2 2522/4885CYP1A1 4203/4885CYP1B1 4682/4885 |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | CD69, NFATC1, CD209 | PTGS2 2488/4885CYP1A1 4306/4885CYP1B1 4744/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | PTGS2 2467/4885CYP1A1 3408/4885CYP1B1 4239/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | PTGS2 2522/4885CYP1A1 4203/4885CYP1B1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.